Platelet Epidermal Growth Factor in Thyroid Disorders

Endocrine Journal

TAKAO FUJINAMI¹  MASAMI OKADA¹  YOSHINOBU KAMIYA¹  HIDEO SHIBATA²  TAKAYUKI YOSHIMATA¹  JUNKO ITO¹  MASANOBU KAWAGUCHI¹ 

[1] Third Department of Internal Medicine, Nagoya City University Medical School;Department of Clinical Laboratory Medicine, Nagoya City University Medical School

关键词: Epidermal growth factor (EGF);    Thyroid hormone;    Platelet;    Graves' disease;    Hypothyroidism;   

DOI  :  10.1507/endocrj.45.83

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(27)Cited-By(2)We evaluated the concentration of epidermal growth factor (EGF) in platelets, serum and plasma obtained from 47 patients with Graves' disease, 7 with hypothyroidism and 20 healthy subjects. The platelets of the subjects were collected from platelet rich plasma and lysed by freezing and thawing. Subsequently the platelet debris was treated with Triton X-100. The EGF concentration was determined by homologous radioimmunoassay. The concentration of EGF in the platelets in 14 patients with untreated Graves' disease was significantly higher than that in the healthy controls. After treating these 14 patients with antithyroid agents, the EGF concentration in the platelets decreased to the level of the healthy controls. The EGF concentration in the platelets in the 7 untreated hypothyroid patients decreased after replacement therapy with thyroxine. The mean volume of the platelets in the 14 patients with untreated Graves' disease was significantly larger than in the control and decreased after treatment with antithyroid agents. The serum and plasma levels of EGF in the 7 untreated hypothyroid increased after replacement therapy. In conclusion, thyroid function affected the concentration of EGF in the platelets of patients with thyroid disorders.

【 授权许可】

Unknown